Application of suramin sodium in the prevention and / or treatment of radiation-induced intestinal injury
Sodium suramin addresses the challenges of preventing and treating radiation-induced intestinal injury by promoting the regeneration of intestinal crypt cells, inhibiting intestinal cell apoptosis, and reducing the secretion of inflammatory factors. It significantly improves intestinal tissue damage and enhances patients' quality of life.
Patent Information
- Application Number
- CN202510005685.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-03
- Publication Date
- 2025-10-31
- Estimated Expiration
- 2045-01-03
AI Technical Summary
Currently, there are no effective drugs to prevent or reduce radiation-induced intestinal damage, which leads to intestinal injury caused by abdominal and pelvic radiotherapy, affecting treatment outcomes and reducing patients' quality of life.
Sodium suramin is used as a drug, administered via intravenous, intramuscular, or subcutaneous injection, to prevent and treat radiation-induced intestinal injury, promote intestinal crypt cell regeneration, inhibit intestinal cell apoptosis, reduce serum inflammatory factor secretion, and improve intestinal tissue pathological damage.
Sodium suramin significantly improves intestinal tissue structure, promotes intestinal crypt cell regeneration, inhibits cell apoptosis, reduces serum inflammatory factor levels, relieves symptoms of inflammation and edema, and effectively prevents and treats radiation-induced intestinal injury.